Results 211 to 220 of about 167,379 (349)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

High‐sensitivity cardiac troponin after cardiac stress test: A systematic review and meta‐analysis [PDF]

open access: yes, 2019
Avila, Audrey   +6 more
core   +1 more source

Sites phosphorylated in bovine cardiac troponin T and I [PDF]

open access: bronze, 1990
Kristine M. Swiderek   +5 more
openalex   +1 more source

A quad‐cistronic fluorescent biosensor system for real‐time detection of subcellular Ca2+ signals

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose The calcium ion (Ca2+) is a versatile cellular messenger regulating a variety of biological processes. Compounds modulating subcellular Ca2+ signals hold substantial pharmacological potential. Advances in fluorescent biosensors have revolutionised Ca2+ imaging.
Anna Lischnig   +7 more
wiley   +1 more source

Pharmacological inhibition of hydroxysteroid 11‐beta dehydrogenase type 1 (11‐βHSD1) after myocardial infarction preserves cardiac function in a translational mini‐pig model

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Plasma glucocorticoids increase acutely after MI, thereafter tissue levels are amplified selectively within cells expressing 11‐ßhydroxysteroid dehydrogenase type 1 (11‐ßHSD1) that regenerates active glucocorticoids from circulating metabolites.
Sara Al Disi   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy